MA41492A - Composés présentant une activité d'antagonistes de récepteur muscarinique et d'agonistes de récepteur bêta 2 adrénergique - Google Patents

Composés présentant une activité d'antagonistes de récepteur muscarinique et d'agonistes de récepteur bêta 2 adrénergique

Info

Publication number
MA41492A
MA41492A MA041492A MA41492A MA41492A MA 41492 A MA41492 A MA 41492A MA 041492 A MA041492 A MA 041492A MA 41492 A MA41492 A MA 41492A MA 41492 A MA41492 A MA 41492A
Authority
MA
Morocco
Prior art keywords
beta
muscarin
compounds showing
showing activity
receptor antagonists
Prior art date
Application number
MA041492A
Other languages
English (en)
Inventor
Laura Carzaniga
Chris Knight
Ian Linney
Fabio Rancati
Andrea Rizzi
Wolfgang Schmidt
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA41492A publication Critical patent/MA41492A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
MA041492A 2015-02-12 2016-02-10 Composés présentant une activité d'antagonistes de récepteur muscarinique et d'agonistes de récepteur bêta 2 adrénergique MA41492A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15154917 2015-02-12

Publications (1)

Publication Number Publication Date
MA41492A true MA41492A (fr) 2021-04-28

Family

ID=52469670

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041492A MA41492A (fr) 2015-02-12 2016-02-10 Composés présentant une activité d'antagonistes de récepteur muscarinique et d'agonistes de récepteur bêta 2 adrénergique

Country Status (26)

Country Link
US (2) US9579314B2 (fr)
EP (1) EP3256464B1 (fr)
JP (1) JP6905466B2 (fr)
KR (1) KR20170115069A (fr)
CN (1) CN107207473B (fr)
AR (1) AR103666A1 (fr)
AU (1) AU2016217955B2 (fr)
BR (1) BR112017017296A2 (fr)
CA (1) CA2976150A1 (fr)
CL (1) CL2017002017A1 (fr)
CO (1) CO2017008031A2 (fr)
EA (1) EA032937B9 (fr)
ES (1) ES2916924T3 (fr)
GE (2) GEAP201914563A (fr)
IL (1) IL253922B (fr)
MA (1) MA41492A (fr)
MX (1) MX369348B (fr)
PE (1) PE20171347A1 (fr)
PH (1) PH12017501424A1 (fr)
PL (1) PL3256464T3 (fr)
SG (1) SG11201706455QA (fr)
TN (1) TN2017000346A1 (fr)
TW (1) TWI703138B (fr)
UA (1) UA124138C2 (fr)
WO (1) WO2016128456A1 (fr)
ZA (1) ZA201705376B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484879B1 (fr) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Composés hydroxyquinoléinoniques ayant une activité antagoniste pour le récepteur muscarinique et une activité agoniste pour le récepteur adrénergique bêta2
JP6963616B2 (ja) * 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2019015640A1 (fr) * 2017-07-21 2019-01-24 四川海思科制药有限公司 Sel de dérivé d'amide azacyclique, sa forme cristalline et son procédé de préparation et son utilisation
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4
WO2019138588A1 (fr) 2018-01-10 2019-07-18 国立大学法人大分大学 Nanofibre de cellulose, matériau stratiforme obtenu à partir de cette dernière, et procédé de production de nanofibre de cellulose et de matériau stratiforme
BR112020023001A2 (pt) 2018-05-15 2021-02-02 Alkahest, Inc. tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase
WO2022165513A1 (fr) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Inhibiteurs de cdk2 et leurs procédés d'utilisation
CA3225439A1 (fr) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Inhibiteurs de cdk2 et leurs procedes d'utilisation
EP4426284A4 (fr) 2021-11-01 2025-11-12 Alkahest Inc Modulateurs de benzodioxane de leucotriène a4 hydrolase (lta4h) pour la prévention et le traitement de maladies liées au vieillissement

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ATE435862T1 (de) * 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005092861A1 (fr) 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006023457A1 (fr) 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
WO2006023460A2 (fr) 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
US8236959B2 (en) * 2007-02-28 2012-08-07 Cipla Limited Process for preparing isomers of carmoterol
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
WO2011048409A1 (fr) * 2009-10-20 2011-04-28 Astrazeneca Ab Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
EP2386555A1 (fr) * 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
RU2606121C2 (ru) * 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
HRP20151317T1 (hr) * 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP3345904B1 (fr) * 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Composés dotés d'activité antagoniste du récepteur muscarinique et agoniste du récepteur adrénergique bêta2

Also Published As

Publication number Publication date
KR20170115069A (ko) 2017-10-16
EP3256464A1 (fr) 2017-12-20
ZA201705376B (en) 2018-12-19
EP3256464B1 (fr) 2022-05-11
CO2017008031A2 (es) 2017-11-10
PL3256464T3 (pl) 2022-07-18
JP6905466B2 (ja) 2021-07-21
MX2017010366A (es) 2018-01-23
TN2017000346A1 (en) 2019-01-16
EA201791579A1 (ru) 2018-02-28
TW201636338A (zh) 2016-10-16
JP2018510137A (ja) 2018-04-12
CL2017002017A1 (es) 2018-04-13
ES2916924T3 (es) 2022-07-06
US20170119753A1 (en) 2017-05-04
CA2976150A1 (fr) 2016-08-18
BR112017017296A2 (en) 2018-04-10
SG11201706455QA (en) 2017-09-28
WO2016128456A1 (fr) 2016-08-18
CN107207473A (zh) 2017-09-26
GEAP201914563A (en) 2019-12-25
UA124138C2 (uk) 2021-07-28
US20160235734A1 (en) 2016-08-18
AR103666A1 (es) 2017-05-24
US9579314B2 (en) 2017-02-28
IL253922A0 (en) 2017-10-31
EA032937B1 (ru) 2019-08-30
PH12017501424B1 (en) 2018-01-15
TWI703138B (zh) 2020-09-01
AU2016217955B2 (en) 2020-03-05
PH12017501424A1 (en) 2018-01-15
PE20171347A1 (es) 2017-09-13
GEP20207098B (en) 2020-04-10
US10004728B2 (en) 2018-06-26
AU2016217955A1 (en) 2017-08-31
EA032937B9 (ru) 2019-11-27
CN107207473B (zh) 2020-07-07
IL253922B (en) 2019-11-28
MX369348B (es) 2019-11-06

Similar Documents

Publication Publication Date Title
EP4069686C0 (fr) Agoniste du récepteur glp-1
MA44729A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP2945630A4 (fr) Antagonistes des récepteurs de l'orexine de type composés de 4-fluoropipéridine
EP3737672A4 (fr) Composés benzamide
MA44085A (fr) Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants
IL247194B (en) Compounds of the cyclopentane type modified in positions 1 and 2 and their use as orexin type receptor antagonists
EP3349814A4 (fr) Matrice extracellulaire soluble non gélifiante présentant une activité biologique
LT3713928T (lt) Nauji bradikinino b2 receptoriaus antagonistai
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
MA40858A (fr) Composés antagonistes des récepteurs d3 à la dopamine
DK3672951T3 (da) Quinoxalinderivater som adenosinreceptorantagonister
EP3438091A4 (fr) Composé ayant une activité d'amélioration pour des actions de récepteur de peptide-1 de type glucagon
IL255937B (en) Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists
EP3709995A4 (fr) Composés bicycliques antidiabétiques
MA41169A (fr) Composés antibactériens à large spectre d'activité
IL258893A (en) Cgrp receptor antagonists
EP3697781C0 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
ZA201800452B (en) Cgrp receptor antagonists
EP3307395A4 (fr) Agents solubilisants pour composés actifs fonctionnels
IL258894A (en) Cgrp receptor antagonists
EP3720445A4 (fr) Agonistes de récepteur adrénergique bêta-2 sélectif
EP3865472C0 (fr) Antagonistes du récepteur de thromboxane
EP3737664A4 (fr) Composés présentant une activité antimicrobienne
EP3693360A4 (fr) Composés hétérocycliques